Cadence Pharmaceuticals, Inc. (CADX)
Q1 2010 Earnings Call Transcript
May 6, 2010 4:30 pm ET
Bill LaRue – SVP, CFO, Treasurer and Assistant Secretary
Ted Schroeder – President and CEO
Eric Schmidt – Cowen and Company
Gary Nachman – Leerink Swan
John Newman – Oppenheimer
Greg Beicher [ph] – Banc of America/Merrill Lynch
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Cadence Pharmaceuticals first quarter 2010 financial results conference call. On the call today is Ted Schroeder, President and CEO; Jim Breitmeyer, Executive Vice President and Chief Medical Officer; and Bill LaRue, Senior Vice President and Chief Financial Officer. At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for questions and answers after the management presentation. (Operator Instructions)
Our first speaker today is Bill LaRue. Go ahead, sir.
Thank you. Good afternoon, everyone. Before we get started today, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward looking statements regarding
our belief that our third party manufacturer will time we resolve FDA's observations with respect to the OFIRMEV manufacturing facility, the timeline from potential for approval of the NDA for OFIRMEV, and our belief that our current cash resources will be sufficient to fund our operations through the approval of the NDA.
All such forward looking statements are based on our current beliefs and expectations, and should not be regarded as a representation that any of our plans will be achieved. Actual results may differ materially from those discussed during this conference call due to the risks and uncertainties inherent in our business, which include